参考文献：

[1] Fiedler L R, Eble J A. Decorin regulates endothelial cell-matrix interactions during angiogenesis[J]. Cell Adh Migr, 2009, 3(1): 3-6.

[2] Scott P G, McEwan P A, Dodd C M, *et al*. Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan[J]. Proc Natl Acad Sci U S A, 2004, 101(44): 15633-15638.

[3] Bi X, Tong C, Dockendorff A, *et al*. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation[J]. Carcinogenesis, 2008, 29(7): 1435-1440.

[4] Ma W, Cai S, Du J, *et al*. SDF-1/54-DCN: a novel recombinant chimera with dual inhibitory effects on proliferation and chemotaxis of tumor cells[J]. Biol Pharm Bull, 2008, 31(6): 1086-1091.

[5] Zafiropoulos A, Nikitovic D, Katonis P, *et al*. Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells[J]. Mol Cancer Res, 2008, 6(5): 785-794.

[6] Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts[J]. Blood, 2008, 112(1): 159-168.

[7] Salomaki H H, Sainio A O, Soderstrom M, *et al*. Differential expression of decorin by human malignant and benign vascular tumors[J]. J Histochem Cytochem, 2008, 56(7): 639-646.

[8] Pucci-Minafra I, Cancemi P, Di-Cara G, *et al*. Decorin transfection induces proteomic and phenotypic modulation in breast cancer cells 8701-BC[J]. Connect Tissue Res, 2008, 49(1): 30-41.

[9] Goldoni S, Humphries A, Nystrom A, *et al*. Decorin is a novel antagonistic ligand of the Met receptor[J]. J Cell Biol, 2009, 185(4): 743-754.

[10] Csordas G, Santra M, Reed C C, *et al*. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth *in vivo*[J]. J Biol Chem, 2000, 275(42): 32879-32887.

[11] Wu H, Wang S, Xue A, *et al*. Overexpression of decorin induces apoptosis and cell growth arrest in cultured rat mesangial cells *in vitro*[J]. Nephrology (Carlton), 2008, 13(7): 607-615.

[12] Matsubara J, Yamada Y, Hirashima Y, *et al*. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer[J]. Clin Cancer Res, 2008, 14(10): 3022-3029.

[13] Kim M A, Lee H S, Lee H E, *et al*. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number[J]. Histopathology, 2008, 52(6): 738-746.

[14] Galizia G, Lieto E, Orditura M, *et al*. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery[J]. World J Surg, 2007, 31(7): 1458-1468.

[15] Magzoub M, Jin S, Verkman A S. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin[J]. FASEB J, 2008, 22(1): 276-284.

[16] Rykova V I, Grigorieva E V, Chernenko A V, *et al*. Proteoglycans and human breast cancer[J]. Bull Exp Biol Med, 2007, 144(3): 335-337.

[17] Shintani K, Matsumine A, Kusuzaki K, *et al*. Decorin suppresses lung metastases of murine osteosarcoma[J]. Oncol Rep, 2008, 19(6): 1533-1539.

[18] 于宏，姜政，王丕龙. pEGFP-N1-TGF-β1 重组质粒对结肠癌细胞增殖、细胞周期及侵袭性的影响[J]. 第三军医大学学报，2010，32(9)：943-946.

[19] Zhang P, Di J Z, Zhu Z Z, *et al*. Association of transforming growth factor-beta 1 polymorphisms with genetic susceptibility to TNM stage Ⅰ or Ⅱ gastric cancer[J]. Jpn J Clin Oncol, 2008, 38(12): 861-866.

（收稿：2010-10-21 修回：2010-11-18）
（编辑 王小寒）

正文中参考文献的标注方法

正文中参考文献的著录制度有顺序编码制和著者-出版年制。

1. 本刊采用顺序编码制，即按照正文中引用的文献出现的先后顺序用阿拉伯数字（从1开始）连续编码，并将序号置于方括号中。

2. 文内标注　　根据具体情况一般可按照下述3种格式标注。

a. 正文指明原始文献作者姓名时，序号标注于作者姓名之后的右上角。

例1：薛社普等[1]指出棉酚从体内排泄缓慢。

b. 正文未指明作者姓名或非原始文献作者时，序号标注于相关论述句末的右上角。

例2：动态心电图特别适用于无症状心肌缺血的发现[1-3]。

c. 正文直接述及文献序号，即文献作正文叙述的直接补语时，文献序号不用角码标注，与正文并排。

例3：本研究与文献[4,6]报道的结果一致。

3. 标注应尽可能靠近有关引文，写在标点符号之前。在同一处同时引用几条文献时，文献序号应放在1个方括号内。文献序号不连续时，用逗号分隔，如例3；连续时文献序号不必一一列出，可标注起止序号，用连接线连接，如例2。

本刊编辑部